Novo Nordisk Wins Favorable Jury Verdict in Whistleblower Action Alleging Off-Label Promotion of Hemophilia Drug
- November 14, 2025
A federal jury in Washington cleared Novo Nordisk Inc. of liability under the False Claims Act (FCA) in a whistleblower action alleging the pharmaceutical manufacturer caused the submission of fraudulent claims to the state’s Medicaid program for its hemophilia drug NovoSeven.
ARTICLE TAGS
You must be logged in to access this content.